In clinical studies, people lost an average of about 11 pounds (5-7% of their body weight)
In Phase 2 trials, the most common side effects were nausea, vomiting, diarrhea, and constipation, consistent with other GLP-1 class drugs
A person who weighs the same at month 10 as they did at month 8 but has gained 3 pounds of muscle and lost 3 pounds of fat looks dramatically different
Obesity & Significant Overweight Semaglutide (Wegovy) is FDA-approved specifically for long-term weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related condition
For individuals at this life stage, a provider may consider a more gradual titration approach based on individual clinical factors
Obesity 31 , 22492259 (2023)